Target intelligence / Profile preview

Natural killer group 2 member D (NKG2D) (NKG2D)

Target
NKG2D
Molecular classification
Receptor, C-type lectin-like receptor
01

Overview

Natural killer group 2 member D (NKG2D) is a major activating receptor found on natural killer (NK) cells, CD8+ T cells, and certain subsets of γδ T cells [1]. It functions as a molecular sensor for induced-self by recognizing stress-induced ligands, such as MICA, MICB, and ULBP proteins, which are typically absent on healthy cells but highly expressed on tumor cells and virally infected cells [2]. Upon ligand binding, NKG2D triggers potent cytotoxic responses and cytokine production to eliminate the target cell [3]. In oncology, this axis is a significant focus for immunotherapy, with strategies including CAR-T and CAR-NK cells engineered with NKG2D, as well as antibodies designed to prevent the shedding of ligands that tumors use to evade immune detection [4]. Despite its therapeutic potential, challenges include the risk of off-tumor toxicity if ligands are expressed on non-malignant stressed tissues and the systemic immunosuppression caused by soluble ligands in the tumor microenvironment [2,3].

Other names
KLRK1CD314Killer cell lectin-like receptor subfamily K member 1NKG2-D type II integral membrane proteinNKG2D-MICA/B axis
02

Mechanism of action

Activation of NK cells and cytotoxic T cells through binding to stress-induced ligands (MICA, MICB, ULBPs) on the surface of transformed or infected cells, leading to targeted cell lysis.

03

Biological functions

Immune responseCell-mediated cytotoxicitySignal transduction
04

Disease associations

CancerAutoimmune diseaseInfection
05

Safety considerations

On-target off-tumor toxicity due to ligand expression on healthy stressed tissuesCytokine release syndrome (CRS)Immune evasion via proteolytic shedding of ligandsPotential for autoimmune reactions
06

Interacting drugs

CYAD-01

4 more in the full profile.

07

Biomarkers

MICA expressionMICB expressionSoluble MICA (sMICA)Soluble MICB (sMICB)ULBP expression

Beyond the preview

Go deeper on Natural killer group 2 member D (NKG2D) (NKG2D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer group 2 member D (NKG2D) (NKG2D).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call